Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort
Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed
Clin Mol Hepatol. 2021;27(3):486-498.   Published online 2021 Feb 23     DOI: https://doi.org/10.3350/cmh.2020.0162
Citations to this article as recorded by Crossref logo
Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
Maral Amangurbanova, Daniel Q. Huang, Rohit Loomba
Alimentary Pharmacology & Therapeutics.2023; 57(1): 37.     CrossRef
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Seung Min Lee, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(1): 171.     CrossRef
Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches
Eirini Martinou, Marinos Pericleous, Irena Stefanova, Vasha Kaur, Angeliki M. Angelidi
Diagnostics.2022; 12(2): 407.     CrossRef
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Algera Goga, Markus Stoffel
Nature Reviews Drug Discovery.2022; 21(6): 417.     CrossRef
Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients
Antonio Gil-Gómez, Ángela Rojas, María R. García-Lozano, Rocío Muñoz-Hernández, Rocío Gallego-Durán, Douglas Maya-Miles, Rocío Montero-Vallejo, Sheila Gato, Javier Gallego, Rubén Francés, Germán Soriano, Javier Ampuero, Manuel Romero-Gómez
International Journal of Molecular Sciences.2022; 23(19): 11840.     CrossRef
Update on genetics and epigenetics in metabolic associated fatty liver disease
Xiaopeng Zhu, Mingfeng Xia, Xin Gao
Therapeutic Advances in Endocrinology and Metabolism.2022; 13: 204201882211321.     CrossRef
No evidence for a causal link between Helicobacter pylori infection and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study
Yuwei Liu, Hongqin Xu, ZiHan Zhao, Yutong Dong, Xiaomei Wang, Junqi Niu
Frontiers in Microbiology.2022;[Epub]     CrossRef
Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology
Camila Cristiane Pansa, Letícia Ramos Molica, Karen C. M. Moraes
Scandinavian Journal of Gastroenterology.2022; : 1.     CrossRef
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gomez, Salvatore Petta, Yusuf Yilmaz, Grace Lai‐Hung Wong, Leon A. Adams, Victor de Lédinghen, Silvia Sookoian, Vincent Wai‐Sun Wong
Hepatology.2022; : n/a.     CrossRef
Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis
Shan Tang, Jing Zhang, Ting-Ting Mei, Wen-Yan Zhang, Su-Jun Zheng, Hai-Bin Yu
BMC Gastroenterology.2021;[Epub]     CrossRef
An analysis of polygenic risk scores for non-alcoholic fatty liver disease
Dae Won Jun
Clinical and Molecular Hepatology.2021; 27(3): 446.     CrossRef